Clinical Trials

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06119581 2026-04-20

SUNRAY-01

1,264 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06623422 2026-04-20

INTerpath-009

680 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT07190248 2026-04-20

KANDLELIT-007

675 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06312137 2026-04-17

TroFuse-019

780 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06452277 2026-04-17

SOHO-02

444 enrolled

Advanced Non-small Cell Lung Cancer

NCT06459180 2026-04-17

TroFuse-020

686 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03520686 2026-04-15

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

102 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06151574 2026-04-15

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

416 enrolled

Lung Neoplasms

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

68 enrolled

Gynecologic

Ovarian Neoplasms

NCT04538664 2026-04-13

PAPILLON

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT06793215 2026-04-13

Krascendo 2

600 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

494 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06875310 2026-04-07

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

630 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07128199 2026-04-07

REZILIENT4

360 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Tumor-Agnostic

Neoplasms

NCT05261399 2026-04-06

SAFFRON

345 enrolled

Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT07418749 2026-04-06

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

398 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06097728 2026-04-02

eVOLVE-Meso

Other solid neoplasmThoracic

825 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT06305754 2026-04-02

MK-2870-009

520 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04205812 2026-03-31

POD1UM-304

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06561386 2026-03-31

RELATIVITY1093

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04129502 2026-03-30

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

354 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06627647 2026-03-27

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

878 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT05555732 2026-03-25

TROPION-Lung07

1,170 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06396065 2026-03-24

Phase III Study of AK112 for NSCLC Patients

420 enrolled

Non-Squamous Non-small Cell Lung Cancer

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

453 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

756 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05984277 2026-03-17

eVOLVE-Lung02

1,200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT06687369 2026-03-11

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

726 enrolled